RU2017144606A - Иммуноцитокины на основе il-15 и il-15rа домена sushi - Google Patents

Иммуноцитокины на основе il-15 и il-15rа домена sushi Download PDF

Info

Publication number
RU2017144606A
RU2017144606A RU2017144606A RU2017144606A RU2017144606A RU 2017144606 A RU2017144606 A RU 2017144606A RU 2017144606 A RU2017144606 A RU 2017144606A RU 2017144606 A RU2017144606 A RU 2017144606A RU 2017144606 A RU2017144606 A RU 2017144606A
Authority
RU
Russia
Prior art keywords
amino acid
acid sequence
conjugate
antibody
paragraphs
Prior art date
Application number
RU2017144606A
Other languages
English (en)
Other versions
RU2763298C2 (ru
RU2017144606A3 (ru
Inventor
Себастьян Даньель МОРИССО
Жеральдин ТЕППА
Янник Лоран Жозеф ЖАК
Бруно Жилбер Марк РОБЕР
МАРТИНОФФ Ги Люк Мишель ДЕ
Давид БЕШАР
Original Assignee
Ситюн Фарма
Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ситюн Фарма, Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) filed Critical Ситюн Фарма
Publication of RU2017144606A publication Critical patent/RU2017144606A/ru
Publication of RU2017144606A3 publication Critical patent/RU2017144606A3/ru
Application granted granted Critical
Publication of RU2763298C2 publication Critical patent/RU2763298C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Claims (16)

1. Конъюгат, содержащий аминокислотную последовательность RLI, соответствующую SEQ ID NO: 17.
2. Конъюгат по п. 1, дополнительно содержащий антитело или фрагмент антитела, способный вступать в реакцию с тем же антигеном, что и антитело, напрямую или опосредованно связанные при помощи ковалентной связи с указанным конъюгатом.
3. Конъюгат по п. 2, где антитело или его фрагмент, связанные при помощи ковалентной связи, содержат тяжелую цепь и/или легкую цепь.
4. Конъюгат по п. 3, где антитело содержит тяжелую цепь, включающую аминокислотную последовательность, соответствующую SEQ ID NO: 19.
5. Конъюгат по п. 3 или 4, где антитело содержит легкую цепь, включающую аминокислотную последовательность, соответствующую SEQ ID NO: 18.
6. Конъюгат по любому из пп. 2-5, где аминокислотная последовательность конъюгата и аминокислотная последовательность антитела или его фрагмента не разделены какой-либо линкерной аминокислотной последовательностью.
7. Конъюгат по любому из пп. 2-5, где аминокислотная последовательность конъюгата и аминокислотная последовательность антитела или его фрагмента разделены второй линкерной аминокислотной последовательностью.
8. Конъюгат по любому из пп. 2-7, где антитело или его фрагмент направлены против антигена, выбранного из группы, содержащей антигены, имеющие отношение к неоваскуляризации опухолей или к внеклеточному матриксу опухоли, и опухолевые антигены.
9. Конъюгат по любому из пп. 2-8, где аминокислотная последовательность конъюгата находится в C-концевом положении относительно аминокислотной последовательности антитела или его фрагмента.
10. Нуклеиновая кислота, кодирующая конъюгат по любому из пп. 1-9.
11. Вектор, содержащий нуклеиновую кислоту по п. 10.
12. Клетка-хозяин, генетически модифицированная нуклеиновой кислотой по п. 10 или вектором по п. 11.
13. Фармацевтическая композиция, содержащая конъюгат по любому из пп. 1-9, нуклеиновую кислоту по п. 10 или вектор по п. 11 и фармацевтически приемлемый носитель.
14. Фармацевтическая композиция по п. 13, где фармацевтически приемлемый носитель представляет собой растворитель, адъювант, эксципиент или наполнитель.
15. Способ лечения рака у субъекта, включающий введение фармацевтической композиции по п. 13 или 14 путем инъекции в дозе 2,5 мг/кг или менее, излечивающей тем самым рак у нуждающегося в этом субъекта.
16. Применение фармацевтической композиции по п. 13 или 14 для изготовления лекарственного средства для лечения рака у нуждающегося в этом субъекта, где лекарственное средство является подходящим для введения путем инъекции в дозе 2,5 мг/кг или менее.
RU2017144606A 2011-06-24 2012-06-22 ИММУНОЦИТОКИНЫ НА ОСНОВЕ IL-15 И IL-15Rα ДОМЕНА SUSHI RU2763298C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11358005A EP2537933A1 (en) 2011-06-24 2011-06-24 An IL-15 and IL-15Ralpha sushi domain based immunocytokines
EP11358005.4 2011-06-24

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2014100350A Division RU2644671C2 (ru) 2011-06-24 2012-06-22 ИММУНОЦИТОКИНЫ НА ОСНОВЕ IL-15 И IL-R[альфа] ДОМЕНА SUSHI

Publications (3)

Publication Number Publication Date
RU2017144606A true RU2017144606A (ru) 2019-03-04
RU2017144606A3 RU2017144606A3 (ru) 2021-02-10
RU2763298C2 RU2763298C2 (ru) 2021-12-28

Family

ID=46456485

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2014100350A RU2644671C2 (ru) 2011-06-24 2012-06-22 ИММУНОЦИТОКИНЫ НА ОСНОВЕ IL-15 И IL-R[альфа] ДОМЕНА SUSHI
RU2017144606A RU2763298C2 (ru) 2011-06-24 2012-06-22 ИММУНОЦИТОКИНЫ НА ОСНОВЕ IL-15 И IL-15Rα ДОМЕНА SUSHI

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2014100350A RU2644671C2 (ru) 2011-06-24 2012-06-22 ИММУНОЦИТОКИНЫ НА ОСНОВЕ IL-15 И IL-R[альфа] ДОМЕНА SUSHI

Country Status (19)

Country Link
US (5) US20150152188A1 (ru)
EP (3) EP2537933A1 (ru)
JP (4) JP6151687B2 (ru)
KR (3) KR20220150407A (ru)
CN (3) CN104093841A (ru)
AU (3) AU2012272138B2 (ru)
BR (1) BR112013033350B1 (ru)
CA (1) CA2840113C (ru)
DK (1) DK2723869T3 (ru)
ES (1) ES2727806T3 (ru)
HR (1) HRP20190799T1 (ru)
HU (1) HUE043442T2 (ru)
MX (1) MX354923B (ru)
PL (1) PL2723869T3 (ru)
PT (1) PT2723869T (ru)
RU (2) RU2644671C2 (ru)
SI (1) SI2723869T1 (ru)
TR (1) TR201907397T4 (ru)
WO (1) WO2012175222A1 (ru)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1324779B1 (en) 2000-09-29 2011-07-20 Schering Corporation Pegylated interleukin-10
WO2007001677A2 (en) 2005-05-17 2007-01-04 University Of Connecticut Compositions and methods for immunomodulation in an organism
ES2668018T3 (es) 2005-12-02 2018-05-16 Icahn School Of Medicine At Mount Sinai Virus quiméricos de la enfermedad de Newcastle que presentan proteínas de superficie no naturales y sus usos
CA2636111C (en) 2006-01-13 2018-04-03 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
BRPI0719446A2 (pt) 2006-09-28 2013-12-10 Schering Corp Uso de il-10 peguilada para tratar câncer
DK2769984T3 (en) 2007-05-11 2017-10-16 Altor Bioscience Corp Fusion molecules and IL-15 variants
ES2466916T3 (es) 2007-06-27 2014-06-11 Admune Therapeutics Llc Complejos de IL-15 e IL-15R alfa y usos de los mismos
EP3851459A1 (en) 2010-09-21 2021-07-21 Altor BioScience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
WO2015089217A2 (en) 2013-12-10 2015-06-18 Bionz, Llc Methods of developing selective peptide antagonists
US9133244B2 (en) 2011-01-18 2015-09-15 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
KR102222157B1 (ko) 2013-03-14 2021-03-03 이칸 스쿨 오브 메디슨 엣 마운트 시나이 뉴캐슬병 바이러스 및 이의 용도
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
US11401312B2 (en) * 2013-04-19 2022-08-02 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
EP3434277A1 (en) 2013-06-17 2019-01-30 Armo Biosciences, Inc. Method for assessing protein identity and stability
DK3030575T3 (en) * 2013-08-08 2018-10-22 Cytune Pharma IL-15 AND IL-15R-ALFA-SUSHI DOMAIN-BASED MODULOKINES
ES2760249T3 (es) * 2013-08-08 2020-05-13 Cytune Pharma Composición farmacéutica combinada
KR20160079114A (ko) 2013-11-11 2016-07-05 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
CA3193936A1 (en) * 2014-01-15 2015-07-23 Kadmon Corporation, Llc Immunomodulatory agents
CN107073099B (zh) 2014-02-27 2022-09-27 默沙东公司 用于治疗癌症的联合方法
EP2915569A1 (en) * 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
WO2016004060A2 (en) * 2014-06-30 2016-01-07 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
US10350270B2 (en) 2014-10-14 2019-07-16 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
MX2017004983A (es) 2014-10-22 2017-11-13 Armo Biosciences Inc Metodos para usar interleucina 10 para tratar enfermedades y trastornos.
PL3235830T3 (pl) * 2014-12-19 2020-12-14 Jiangsu Hengrui Medicine Co., Ltd. Kompleks białkowy interleukiny 15 i jego zastosowanie
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
JP6730705B2 (ja) * 2015-02-12 2020-07-29 国立大学法人岩手大学 哺乳動物細胞に対する外来遺伝子の導入効率の向上剤
KR20180020141A (ko) 2015-05-28 2018-02-27 아르모 바이오사이언시스 인코포레이티드 암 치료에 사용되는 peg화된 인터류킨-10
US20180155439A1 (en) * 2015-06-10 2018-06-07 Emory University Compositions and Conjugates Comprising an Interleukin and Polypeptides That Specifically Bind TGF-beta
CN112574316A (zh) * 2015-07-02 2021-03-30 博际生物医药科技(杭州)有限公司 用于肿瘤靶向治疗的白细胞介素-15融合蛋白
US10398761B2 (en) 2015-08-25 2019-09-03 Armo Biosciences, Inc. Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers
WO2017046200A1 (en) * 2015-09-16 2017-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Specific interleukin-15 (il-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases
JP7461620B2 (ja) 2015-10-06 2024-04-04 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 治療用化合物及び方法
CA3000207A1 (en) * 2015-10-09 2017-04-13 Bioniz, Llc Modulating gamma-c-cytokine activity
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
WO2017201352A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Mrna combination therapy for the treatment of cancer
AU2017283480A1 (en) 2016-06-13 2019-01-24 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
EP3526240A1 (en) 2016-10-14 2019-08-21 Xencor, Inc. Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
EP3529263A4 (en) * 2016-10-21 2020-07-08 Altor BioScience Corporation MULTIMERIC MOLECULES BASED ON IL-15
KR20190082263A (ko) * 2016-11-02 2019-07-09 나노프로테아젠 중합체 나노입자
CN108250301A (zh) * 2016-12-29 2018-07-06 天津天锐生物科技有限公司 一种多靶点嵌合抗原受体
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
TW201904993A (zh) 2017-06-22 2019-02-01 瑞士商諾華公司 IL-1β 結合抗體之用途
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
PE20200717A1 (es) 2017-06-22 2020-07-21 Novartis Ag Moleculas de anticuerpo que se unen a cd73 y usos de las mismas
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
CA3066747A1 (en) 2017-06-27 2019-01-03 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof
CN111132733A (zh) 2017-06-30 2020-05-08 Xencor股份有限公司 含有IL-15/IL-15Rα和抗原结合结构域的靶向异源二聚体Fc融合蛋白
JP2020527572A (ja) 2017-07-20 2020-09-10 ノバルティス アーゲー 抗ｌａｇ−３抗体の投薬量レジメンおよびその使用
CN111432836A (zh) 2017-09-05 2020-07-17 转矩医疗股份有限公司 治疗性蛋白质组合物及其制备和使用方法
CA3081602A1 (en) 2017-11-16 2019-05-23 Novartis Ag Combination therapies
TW201925782A (zh) 2017-11-30 2019-07-01 瑞士商諾華公司 靶向bcma之嵌合抗原受體及其用途
SG11202004833SA (en) * 2017-12-08 2020-06-29 Fate Therapeutics Inc IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS
CU24545B1 (es) * 2017-12-29 2021-09-07 Ct Ingenieria Genetica Biotecnologia Péptido antagonista de la actividad de la interleucina-15
EP3752203A1 (en) 2018-02-13 2020-12-23 Novartis AG Chimeric antigen receptor therapy in combination with il-15r and il15
WO2019165453A1 (en) 2018-02-26 2019-08-29 Synthorx, Inc. Il-15 conjugates and uses thereof
KR20200128116A (ko) 2018-02-28 2020-11-11 화이자 인코포레이티드 Il-15 변이체 및 이의 용도
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
CA3097741A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
MX2020010910A (es) 2018-04-18 2021-02-09 Xencor Inc Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
EP3561053A1 (en) * 2018-04-26 2019-10-30 Baylor College of Medicine Immune effector cells and molecular adaptors with an antigen cytokine complex for effective cancer immunotherapy
CN110437339B (zh) * 2018-05-04 2021-08-13 免疫靶向有限公司 一种以白介素15为活性成分的融合蛋白型药物前体
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
TW202016136A (zh) 2018-06-01 2020-05-01 瑞士商諾華公司 針對ｂｃｍａ之結合分子及其用途
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
CA3109361A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Single-chain and multi-chain chimeric polypeptides and uses thereof
SG11202101780WA (en) 2018-08-30 2021-03-30 Hcw Biologics Inc Single-chain chimeric polypeptides and uses thereof
JP7397874B2 (ja) 2018-08-30 2023-12-13 エイチシーダブリュー バイオロジックス インコーポレイテッド 多鎖キメラポリペプチドおよびその使用
US11377477B2 (en) 2018-10-12 2022-07-05 Xencor, Inc. PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof
EP3897637A1 (en) 2018-12-20 2021-10-27 Novartis AG Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CN113438961A (zh) 2018-12-20 2021-09-24 Xencor股份有限公司 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
US20200369762A1 (en) 2018-12-21 2020-11-26 Novartis Ag Use of il-1beta binding antibodies
KR20210108422A (ko) 2018-12-21 2021-09-02 노파르티스 아게 IL-1β 결합 항체의 용도
US20220025036A1 (en) 2018-12-21 2022-01-27 Novartis Ag Use of il-1beta binding antibodies
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
CN113329792A (zh) 2019-02-15 2021-08-31 诺华股份有限公司 取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
EA202192019A1 (ru) 2019-02-15 2021-11-02 Новартис Аг Производные 3-(1-оксо-5-(пиперидин-4-ил)изоиндолин-2-ил)пиперидин-2,6-диона и пути их применения
CA3136241A1 (en) 2019-05-20 2020-11-26 Ulrich Moebius Il-2/il-15r.beta.y agonist dosing regimens for treating cancer or infectious diseases
WO2020249757A1 (en) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
AU2020294797A1 (en) 2019-06-21 2021-12-23 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
US11058725B2 (en) 2019-09-10 2021-07-13 Obsidian Therapeutics, Inc. CA2 compositions and methods for tunable regulation
EP4031578A1 (en) 2019-09-18 2022-07-27 Novartis AG Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
RU2753282C2 (ru) * 2019-09-19 2021-08-12 Закрытое Акционерное Общество "Биокад" ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
BR112022007376A2 (pt) 2019-10-21 2022-07-05 Novartis Ag Terapias de combinação com venetoclax e inibidores de tim-3
JP2022553306A (ja) 2019-10-21 2022-12-22 ノバルティス アーゲー Ｔｉｍ－３阻害剤およびその使用
CN115551594A (zh) * 2019-10-24 2022-12-30 米诺陶治疗公司 经细胞因子修饰的嵌合抗体及其使用方法
CN111690068B (zh) * 2019-11-13 2022-04-19 中国科学技术大学 一种IL-15/SuIL-15Rα-dFc-γ4复合体蛋白及其构造方法、应用
KR20220131895A (ko) 2019-11-21 2022-09-29 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 항-pd-1/il-15 면역사이토카인을 이용하여 pd-1을 표적으로 하는 신규한 면역요법
CN113135996A (zh) * 2019-12-09 2021-07-20 启愈生物技术(上海)有限公司 一种双特异抗体及其应用
BR112022011902A2 (pt) 2019-12-20 2022-09-06 Novartis Ag Terapias de combinação
CA3167413A1 (en) 2020-01-17 2021-07-22 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
EP3889183A1 (en) * 2020-04-01 2021-10-06 Pierre Fabre Medicament A protein complex comprising an immunocytokine
MX2022015852A (es) 2020-06-23 2023-01-24 Novartis Ag Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP4204020A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
EP4204021A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
EP4232068A1 (en) 2020-10-26 2023-08-30 Cytune Pharma IL-2/IL-15RBetaGamma AGONIST FOR TREATING NON-MELANOMA SKIN CANCER
AU2021367887A1 (en) 2020-10-26 2023-06-01 Cytune Pharma IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA
WO2022097060A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CA3217520A1 (en) * 2021-04-22 2022-10-27 Guangdong Fapon Biopharma Inc. Bispecific multifunctional fusion polypeptide
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
CA3220418A1 (en) 2021-06-23 2022-12-29 Guy Luc Michel De Martynoff Interleukin 15 variants
WO2023017191A1 (en) 2021-08-13 2023-02-16 Cytune Pharma Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer
WO2023083379A1 (zh) * 2021-11-15 2023-05-19 中国科学院生物物理研究所 一种以白介素15为活性成份的融合蛋白构建体及其应用
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
CN116854821A (zh) * 2022-08-15 2023-10-10 海徕科(北京)生物技术有限公司 IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US576A (en) * 1838-01-20 Ftjbnace of stoves fob bubning anthracite
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
GB2148299B (en) 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
PH26813A (en) 1987-09-02 1992-11-05 Ciba Geigy Ag Conjugates of cytokines with immunoglobulins
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5997856A (en) 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108910A (en) 1989-08-22 1992-04-28 Immunex Corporation DNA sequences encoding fusion proteins comprising GM-CSF and IL-3
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
EP0531472B1 (en) 1991-03-06 2003-08-13 MERCK PATENT GmbH Humanized monoclonal antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DK0669836T3 (da) * 1992-11-13 1996-10-14 Idec Pharma Corp Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
DE69425906T2 (de) 1994-04-06 2001-03-29 Immunex Corp Interleukin-15
US6287865B1 (en) 1995-03-31 2001-09-11 Plant Bioscience Limited Cf-2 plant pathogen resistance genes
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO2000047228A1 (en) 1999-02-12 2000-08-17 The Scripps Research Institute Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
US6319796B1 (en) 1999-08-18 2001-11-20 Vlsi Technology, Inc. Manufacture of an integrated circuit isolation structure
JP4896327B2 (ja) 1999-08-23 2012-03-14 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド Ｐｄ−１、ｂ７−４の受容体、およびその使用
WO2001014556A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Novel b7-4 molecules and uses therefor
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
WO2001039722A2 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
JP4254051B2 (ja) 2000-11-15 2009-04-15 日本精工株式会社 トロイダル型無段変速機
KR100900176B1 (ko) 2001-03-07 2009-06-02 메르크 파텐트 게엠베하 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술
CA2469151C (en) * 2001-12-04 2013-08-13 Merck Patent Gesellschaft Mit Beschraenkter Haftung Immunocytokines with modulated selectivity
DE10212442A1 (de) 2002-03-20 2003-10-09 Michael Hesse Süßwasseraufbereitungsanlage und Verfahren zur Trinkwassergewinnung
US7906118B2 (en) 2005-04-06 2011-03-15 Ibc Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
KR101348472B1 (ko) 2002-10-17 2014-01-07 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
ATE516305T1 (de) 2004-02-27 2011-07-15 Inst Nat Sante Rech Med Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonisten
US20060025885A1 (en) 2004-08-02 2006-02-02 The Form House, Inc. Apparatus and method for loading data storage devices into carriers
WO2007001677A2 (en) * 2005-05-17 2007-01-04 University Of Connecticut Compositions and methods for immunomodulation in an organism
EP1777294A1 (en) * 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
CA2636111C (en) 2006-01-13 2018-04-03 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
EA200802289A1 (ru) 2006-05-08 2009-04-28 Филоджен Спа Направляемые к мишени антителами цитокины для терапии
FR2906808B1 (fr) 2006-10-10 2012-10-05 Univ Nantes Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers
DK2769984T3 (en) 2007-05-11 2017-10-16 Altor Bioscience Corp Fusion molecules and IL-15 variants
ES2466916T3 (es) * 2007-06-27 2014-06-11 Admune Therapeutics Llc Complejos de IL-15 e IL-15R alfa y usos de los mismos
CA2720628A1 (en) 2007-07-26 2009-01-29 Novagen Holding Corporation Fusion proteins having mutated immunoglobulin hinge region
AU2009228158B2 (en) 2008-03-27 2014-02-27 Zymogenetics, Inc. Compositions and methods for inhibiting PDGFRbeta and VEGF-A
WO2009135031A1 (en) 2008-04-30 2009-11-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Substituted il-15
IN2012DN01663A (ru) 2009-09-16 2015-06-05 Immunomedics Inc
WO2011070214A2 (es) * 2009-12-11 2011-06-16 Proyecto De Biomedicina Cima S.L. Conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
EP2723380B1 (en) 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
PT2785375T (pt) 2011-11-28 2020-10-29 Merck Patent Gmbh Anticorpos anti-pd-l1 e usos destes
CA2888896A1 (en) 2012-10-24 2014-05-01 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes

Also Published As

Publication number Publication date
AU2012272138B2 (en) 2017-07-20
AU2017245360A1 (en) 2017-11-02
CA2840113A1 (en) 2012-12-27
DK2723869T3 (da) 2019-05-20
MX2013015393A (es) 2015-04-08
US20210147503A1 (en) 2021-05-20
CA2840113C (en) 2024-02-27
CN104093841A (zh) 2014-10-08
BR112013033350B1 (pt) 2023-10-31
HUE043442T2 (hu) 2019-08-28
BR112013033350A2 (pt) 2017-01-31
EP2537933A1 (en) 2012-12-26
JP6913073B2 (ja) 2021-08-04
JP6151687B2 (ja) 2017-06-21
CN108341884A (zh) 2018-07-31
US10899816B2 (en) 2021-01-26
KR20140062030A (ko) 2014-05-22
US10626155B2 (en) 2020-04-21
JP2021098698A (ja) 2021-07-01
KR20210016072A (ko) 2021-02-10
PT2723869T (pt) 2019-06-04
KR20190051080A (ko) 2019-05-14
EP2723869A1 (en) 2014-04-30
MX354923B (es) 2018-03-26
EP2723869B1 (en) 2019-02-27
TR201907397T4 (tr) 2019-06-21
AU2019240556A1 (en) 2019-10-17
AU2012272138A1 (en) 2014-01-16
KR20220150407A (ko) 2022-11-10
SI2723869T1 (sl) 2019-08-30
CN114805606A (zh) 2022-07-29
EP3406723A1 (en) 2018-11-28
JP6452175B2 (ja) 2019-01-16
AU2019240556B2 (en) 2022-01-13
US11753454B2 (en) 2023-09-12
HRP20190799T1 (hr) 2019-08-23
JP2017184750A (ja) 2017-10-12
RU2644671C2 (ru) 2018-02-13
US20150152188A1 (en) 2015-06-04
US20180312560A1 (en) 2018-11-01
WO2012175222A1 (en) 2012-12-27
US20240083963A1 (en) 2024-03-14
ES2727806T3 (es) 2019-10-18
WO2012175222A8 (en) 2018-08-23
AU2017245360B2 (en) 2019-07-18
KR101977312B1 (ko) 2019-05-13
JP2014524737A (ja) 2014-09-25
RU2014100350A (ru) 2015-07-27
PL2723869T3 (pl) 2019-09-30
US20160318986A1 (en) 2016-11-03
JP7296999B2 (ja) 2023-06-23
RU2763298C2 (ru) 2021-12-28
RU2017144606A3 (ru) 2021-02-10
JP2019054816A (ja) 2019-04-11

Similar Documents

Publication Publication Date Title
RU2017144606A (ru) Иммуноцитокины на основе il-15 и il-15rа домена sushi
AU2021218097B2 (en) A novel complex comprising a cell penetrating peptide, a cargo and a TRL peptide agonist
US20220118102A1 (en) Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine
Sun Peptide-based drug development
JP2019107018A5 (ru)
JP2021502810A5 (ru)
NZ601818A (en) Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers
RU2011144089A (ru) Композиции вакцин и способы их применения
JP2012522802A5 (ru)
RU2015143208A (ru) Высокоаффинные антитела kgd2
RU2016106339A (ru) Анти-неr2 антитело и его конъюгат
RU2012129208A (ru) Конъюгаты и композиции для иммунотерапии и противоопухолевого лечения
NZ713461A (en) Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
JP2010529026A5 (ru)
JP2012100677A5 (ru)
JP2014506135A5 (ru)
RU2012137498A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
JP2013528229A5 (ru)
JP2017523985A5 (ru)
AU2017331949A1 (en) Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer
JP2014502961A5 (ru)
JP2014502955A5 (ru)
RU2014140116A (ru) Антитела против pdgf-c
WO2020006312A1 (en) Targeting of multiple antigens with multiplex car t cells in solid and liquid malignancies
Demircan et al. Biotin Functionalized Self‐Assembled Peptide Nanofiber as an Adjuvant for Immunomodulatory Response